Originally posted on CBS Detroit:
FLINT — Diplomat Specialty Pharmacy and South San Francisco, Calif.-based Exelixis Inc. (Nasdaq: EXEL) announced Monday that it had been selected as the exclusive specialty pharmacy for Cometriq (cabozantinib).
Cometriq was approved by the U.S. Food and Drug Administration for the treatment of progressive, metastatic medullary thyroid cancer on Nov. 29.
The recommended dose of Cometriq is 140 mg orally, once daily (one 80 mg capsule and three 20 mg capsules). Cometriq should not be taken with food, and patients are advised to not eat for at least 2 hours before and at least 1 hour after taking Cometriq. The Cometriq label has boxed warnings concerning risk of perforations and fistulas, and hemorrhage. Full prescribing information, including Boxed Warning, is available at www.exelixis.com or www.cometriq.com.
Diplomat, the nation’s largest privately owned specialty pharmacy, was chosen as the exclusive distributor for this product due to its commitment to high-touch patient care. Diplomat’s focus…
View original 237 more words